Fortress Biotech (FBIO) Net Cash Flow Growth (3y) (2013 - 2025)
Powered by 
Analysis
Fortress Biotech (FBIO) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 4.55% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 52.78% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 38.66% |
| Sep 30, 2025 | 31.86% |
| Jun 30, 2025 | 24.08% |
| Mar 31, 2025 | 56.74% |
| Dec 31, 2024 | -26.81% |
| Sep 30, 2024 | 7.99% |
| Jun 30, 2024 | 20.20% |
| Mar 31, 2024 | -64.77% |
| Dec 31, 2023 | -16.79% |
| Sep 30, 2023 | -39.53% |
| Jun 30, 2023 | -50.20% |
| Mar 31, 2023 | -205.28% |
| Dec 31, 2022 | -142.58% |
| Sep 30, 2022 | -40.86% |
| Jun 30, 2022 | -46.98% |
| Mar 31, 2022 | -33.10% |
| Dec 31, 2021 | 93.00% |
| Sep 30, 2021 | -59.63% |
| Jun 30, 2021 | 14.13% |
| Mar 31, 2021 | 78.33% |